What to tell patients who ask about psychedelic treatment options

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed healthcare professionals whose patients are asking about psilocybin, ketamine, MDMA, or other psychedelic treatment options — covering what to say, how to say it, and where the clinical and legal boundaries of that conversation sit.

The short answer

When a patient asks about psychedelic treatment options, the clinician’s job is to give them accurate, honest information that supports their autonomous decision-making — not to advocate for or against psilocybin, and not to avoid the topic because it feels legally uncertain. Under HB 2387, clinicians regulated by seven specified Oregon boards are now explicitly protected from board discipline for discussing psilocybin services with patients. The conversation that protects both the patient and the clinician is one that accurately represents what the evidence shows, what the legal options are, what the access and financial realities are, and what the patient needs to know before deciding. This article provides a framework for that conversation.

What patients are typically asking

When a patient raises psychedelic treatment options, they are usually asking one or more of four questions: Is this real — does it actually work? Is it legal? How do I access it? And should I do it?

The clinical conversation addresses all four, in that order. Starting with legality before establishing that the patient understands the evidence base tends to produce conversations that feel like gatekeeping. Starting with evidence — and being honest about both what it shows and what it does not — puts the patient in a position to make an informed choice about whether and how to pursue access.

What the evidence shows

For patients asking about psilocybin specifically, the honest clinical summary as of early 2026 is:

The strongest evidence base is for treatment-resistant depression. COMPASS Pathways’ Phase 3 trials (COMP005, June 2025; COMP006, February 2026) met their primary endpoints for TRD, and a rolling NDA submission is planned for late 2026. The trial data — more than 1,000 participants across Phase 2b and the two Phase 3 trials — represents the strongest controlled evidence for any psychedelic treatment. A clinician can tell a patient with TRD that the evidence for psilocybin’s potential in their condition is substantial and continues to strengthen.

Meaningful evidence also exists for major depressive disorder, end-of-life existential distress, alcohol use disorder, and tobacco dependence. For end-of-life distress specifically, the data is among the most consistent in the literature, with effects durable at four-plus years in some studies.

Honest qualification of the evidence matters. The patient population in most trials has been predominantly white, educated, and psychologically sophisticated — limiting generalizability. Effective blinding is inherently difficult in psychedelic trials. Long-term safety data beyond 12 months remain limited. And the role of the therapeutic support component — how much outcomes depend on the specific preparation and integration model — has not been fully disentangled from psilocybin’s pharmacological effects.

A clinician who tells a patient that psilocybin will treat their depression is overstating the evidence. A clinician who tells a patient the evidence is promising but not yet definitive, that outcomes vary significantly between individuals, and that the clinical trial context differs from Oregon’s licensed program context, is giving an accurate picture.

What the legal options are

Oregon’s licensed psilocybin program is the only state-regulated wellness access pathway currently operating in the United States for psilocybin, alongside Colorado’s program (first sessions June 2025) and New Mexico’s program (effective June 2025, implementation by end of 2027). A clinician can tell a patient where these programs exist, that they operate under state law, that psilocybin remains federally scheduled, and that access through these programs involves facilitators rather than prescribing clinicians.

For ketamine, the picture is different. Esketamine (Spravato) is FDA-approved for TRD and available through REMS-certified facilities with standard insurance coverage. IV ketamine for depression is legal off-label prescribing, cash-pay only for psychiatric indications. A patient who is asking about ketamine as a psychedelic-adjacent option can be given a clear description of both pathways and their respective access realities.

For MDMA-assisted therapy, the FDA’s August 2024 complete response letter declined to approve Lykos Therapeutics’ application. As of early 2026, no FDA-approved MDMA pathway exists and no legal MDMA access is available outside of clinical trials. A clinician whose patient is asking about MDMA therapy should be clear about this.

What access actually looks like

Oregon’s psilocybin program: no prescription or clinician referral required; the patient contacts a licensed service center directly through the OPS Licensee Directory at oregon.gov/psilocybin; cost is typically $1,200–$3,000 per session entirely out-of-pocket; 25 of 36 Oregon counties have opted out, concentrating service centers along the I-5 corridor; waitlists exist particularly for lower-cost options. Colorado’s program has similar structure and pricing. New Mexico’s program is medical model requiring a qualifying diagnosis.

A clinician whose patient has geographic or financial barriers to access can be honest that those barriers are real — and can discuss the alternatives covered in article 42 of this library, including clinical trials, international options, and other legal pathways.

What the patient needs to know before deciding

Several things are worth naming explicitly in a clinical conversation about psilocybin access that are not typically part of standard medication discussions.

Psilocybin experiences are highly variable. Research results are averages. A patient’s individual experience may be profound, neutral, challenging, or frightening. Some patients find difficult experiences ultimately meaningful; others do not. This is worth naming rather than eliding.

The experience may produce changes the patient did not intend. High-dose psilocybin can shift personality, worldview, and the patient’s relationship to their core beliefs. A patient can understand intellectually that this may happen, but cannot fully assess in advance whether the changed version of themselves will endorse the values the pre-session version holds. Naming this — not as a reason to discourage access, but as something the patient should think about — is part of honest preparation.

Psilocybin can surface trauma. A patient with unprocessed or undisclosed trauma should have a clear plan for clinical support in the weeks following the session before they proceed, not after.

Integration matters. Research consistently shows that without meaningful integration support — ways of working with the experience after it occurs — the initial effects of psilocybin may fade. A patient who has ongoing clinical support from a clinician is in a better position to integrate than one who does not. The OPS facilitation model provides a 72-hour check-in and optional integration sessions, but the facilitator’s role is non-directive. Clinical integration support from a licensed provider is something the patient should plan for.

What to review before the patient proceeds

The most concrete clinical contribution a prescribing clinician can make is medication review. A patient on lithium cannot access the Oregon program without a supervised 30-day washout. A patient on an MAOI needs a planned 2-week washout. A patient on SSRIs or SNRIs should understand that their medications may substantially reduce the subjective effects and discuss whether that matters for their goals. See What clinicians need to know about screening patients for psychedelic services for the full clinical picture.

Patients for whom the conversation warrants extra care

Patients with a history of active psychosis are formally excluded from Oregon’s program. Patients with significant cardiovascular conditions, complex psychiatric presentations, or fragile psychological stability are not formally excluded but warrant more careful clinical discussion about whether access is appropriate and what preparation and support look like.

Patients who are motivated by desperation — who have exhausted many other options and are placing significant hope in psilocybin — may have an elevated expectation of benefit that a clinician’s honest engagement can help calibrate without dismissing their hope.

Billing and insurance

The clinical services surrounding a patient’s psilocybin access — medication review, preparation-focused clinical sessions, integration therapy — may be billable through standard clinical codes when provided by a licensed clinician for a diagnosed condition. The psilocybin session itself cannot be billed. A clinician who structures their engagement to distinguish the billable clinical components from the psilocybin access pathway can help a patient use their insurance for the clinical work surrounding the experience, even though the session itself is out-of-pocket.

When public information may be enough

The OPS Licensee Directory and program information are at oregon.gov/psilocybin. COMPASS Pathways’ Phase 3 trial data is available through peer-reviewed publications and investor disclosures. The FDA’s Spravato prescribing information and REMS program are at fda.gov. HB 2387’s discussion protection provisions are available through the Oregon Legislative Assembly.

When you should speak with a lawyer

A clinician who has received a board inquiry or patient complaint related to a psilocybin discussion should retain counsel before responding. A clinician regulated by a board not named in HB 2387 who wants to understand their exposure before engaging in clinical psilocybin conversations should consult an attorney first. A clinician who wants to structure a practice involving pre-session medication management, integration therapy, or dual-licensed facilitation should get legal and insurance advice before beginning.

You might also want to read

This article is for general informational purposes only and does not constitute legal or medical advice. The evidence base and regulatory framework for psychedelic treatment options change rapidly. For clinical guidance specific to your patients, consult current peer-reviewed literature and appropriate clinical authorities.